Clay Siegall of Seattle Genetics

Seattle Genetics is the largest biotech company in Washington State. Since 2014, its sales have increased by almost 50%. The stock price for this publicly traded company has also shot up over the past few years, tripling since 2012. As founder and CEO, Siegall is presiding over a real powerhouse.

Currently, Seattle Genetics is focused on the study of oncology. Cancer is a disease that touches nearly every family in America. This company seeks to help bring recovery to millions, and has more than ten drugs in development.

Adcetris, designed to treat Hodgkin lymphoma, is perhaps the most promising and has been fast-tracked by the FDA. Another is 33A, designed to treat acute myeloid leukemia. AML is a tough cancer, for which there are few treatments. Seattle Genetics is trying to turn this around and give patients with that diagnosis more hope.

Clay Siegall is the engine for much of the company’s success. He has been with Seattle Genetics since the beginning. In 1998, he was one of the co-founders. He has shepherded the company through funding rounds where they raised over $600 million. Siegall was there for the 2001 IPO, too. Today, he remains on board as President and CEO.

Siegall loves the entrepreneurial aspects of his job, and insists that he is not courting a buyout. He started his career at pharmaceutical giant Bristol-Myers Squibb in the early 1990s. He feels that in spite of a changing political climate, Seattle Genetics has a promising future. The company is at just the right size. It’s small enough to remain nimble and innovative, while still being large enough to make a big difference.

In addition to his decades of experience in business, Siegall is a well-trained scientist. He earned his BS at the University of Maryland. He completed a PhD in Genetics at George Washington University.